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AbstrAct
The pro- or anti-inflammatory activities of immunoglobulins G (IgGs) are 
controlled by the structure of the glycan N-linked to Asn297 of their heavy chain. The 
age-associated low grade inflammation (inflammaging) is associated with increased 
plasmatic levels of agalactosylated IgGs terminating with N-acetylglucosamine 
(IgG-G0) whose biogenesis has not been fully explained. Although the biosynthesis 
of glycans is in general mediated by glycosyltransferases associated with internal 
cell membranes, the extracellular glycosylation of circulating glycoproteins mediated 
by plasmatic glycosyltransferases has been recently demonstrated. In this study 
we have investigated the relationship between plasmatic glycosyltransferases, 
IgG glycosylation and inflammatory and aging markers. In cohorts of individuals 
ranging from infancy to centenarians we determined the activity of plasmatic β4 
galactosyltransferase(s) (B4GALTs) and of α2,6-sialyltransferase ST6GAL1, the 
glycosylation of IgG, the GlycoAge test (a glycosylation-based marker of aging) and 
the plasma level of inflammatory and liver damage markers. Our results show that: 
1) plasmatic B4GALTs activity is a new marker of aging, showing a linear increase 
throughout the whole age range. 2) plasmatic ST6GAL1 was high only in children and 
in people above 80, showing a quadratic relationship with age. 3) Neither plasmatic 
glycosyltransferase correlated with markers of liver damage. 4) plasmatic ST6GAL1 
showed a positive association with acute phase proteins in offspring of short lived 
parents, but not in centenarians or in their offspring. 5) Although the glycosylation 
of IgGs was not correlated with the level of the two plasmatic glycosyltransferases, 
it showed progressive age-associated changes consistent with a shift toward a pro-
inflammatory glycotype.
INtrODUctION
Aging has been recently proposed as a continuation 
of developmental growth [1] and is characterized by a 
chronic, low grade, asymptomatic process, defined as 
“inflammaging” [2-5], whose individual level is related 
to biological age and risk of age-related diseases. Thus, 
the identification of new biomarkers of biological aging 
is highly relevant to profile the general health conditions 
of elderly population and to assess the impact of different 
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life styles on aging. 
Glycosylation, one of the most frequent 
postranslational modifications of proteins, undergoes 
profound changes associated with aging, cancer and 
inflammatory conditions [6-8]. Protein-linked sugar 
chains often modulate the biological functions of 
the glycoprotein. A good example is provided by the 
asparagine-linked (N-linked) sugar chain attached 
to Asn
297
 of IgG which, according to the presence or 
absence of specific terminal sugars, modulate the pro- 
or anti inflammatory properties of the antibody [9, 10]. 
It is known since the ’80s that the blood of rheumatoid 
arthritis patients contains IgG molecules with sugar 
chains lacking sialic acid and galactose and terminating 
with N-acetylglucosamine (GlcNAc), which are referred 
to as IgG-G0 [11]. Increased presence of IgG-G0 was 
described subsequently in blood of aging people [12] and 
in a variety of other inflammatory conditions (reviewed in 
[8]). The GlycoAge test is a widely recognized glycosidic 
marker of biological age [13-16], based on the relative 
abundance, in plasmatic glycoproteins, of two N-glycan 
species (an agalactosylated core fucosylated biantennary 
and a bigalactosylated, core fucosylated biantennary), as 
detected by DNA sequencer-aided fluorophore assisted 
carbohydrate electrophoresis (DSA-FACE) [17]. 
The biosynthesis of the sugar chains is mediated 
by glycosyltransferases, a class of enzymes which 
usually transfer single monosaccharides from sugar-
nucleotide donors to sugar chains. Glycosyltransferases 
are classified according to the monosaccharide they 
transfer (galactosyltransferases, sialyltransferases etc.) 
and are present in cell bound forms, mainly associated 
with internal membranes, but also in soluble forms in 
body fluids [18-20]. The biogenesis of IgG-G0 in aging 
has never been investigated, while conflicting results have 
been reported on the biogenesis of IgG-G0 in rheumatoid 
arthritis (RA) patients. In fact, some studies reported 
unchanged expression of galactosyltransferase in B 
lymphocytes of RA patients [21-24], while others reported 
decreased expression [25-28]. It has long been thought 
that soluble plasmatic glycosyltransferases could not 
transfer sugars to circulating glycoproteins because of the 
insufficient concentration of the appropriate nucleotide-
sugar donors. However, this view has recently been 
challenged by the finding that extracellular glycosylation 
can take place using the sugar nucleotide donors 
contained in platelets [29, 30]. Thus, the possibility that 
the glycosylation of plasmatic glycoproteins, including 
IgG, might be mediated by soluble glycosyltransferases 
should be taken into consideration [31]. In the present 
study we have measured in plasma of a cohort of 
individuals ranging from infancy to centenarians, the 
activity of α2,6-sialyltransferase ST6GAL1 and of β4-
galactosyltransferases (B4GALTs), enzymes which might 
be crucial for the level of IgG-G0 and of anti-inflammatory 
α2,6-sialylated IgG, determined the GlycoAge test 
and studied the glycosylation of IgG. Finally, the two 
plasmatic glycosyltransferase activities were correlated 
with metabolic and inflammatory markers in centenarians, 
persons with a genetic background putatively bound to 
extreme longevity, in a group of centenarian’s offspring, 
characterized by higher probability to become long-lived, 
and in the offspring of non-long lived parents. 
rEsULts
Plasmatic st6GAL1 and b4GALts activity in 
subjects of different ages
The level of ST6GAL1 and B4GALTs was measured 
in the plasma of individuals of both gender belonging 
to six age groups: children, young, middle aged, old, 
oldest old and centenarians. Details on the subjects are 
described in Materials and Methods. The acceptor used 
for sialyltransferase activity ensures good specificity for 
ST6GAL1, while that used for galactosyltransferase(s) 
can putatively detect the products of different B4GALT 
genes, although B4GALT1 is probably the major. For 
these reasons the two activities will be thereafter referred 
to as ST6GAL1 and B4GALTs. Correlation analysis 
showed a highly significant linear positive relationship 
(R2 = 0.466; p < 0.00001) of plasmatic B4GALTs with 
age from infancy to centenarians (Figure 1A). On the 
contrary, sialyltransferase ST6GAL1 displayed a highly 
significant quadratic relationship (R2 = 0.292, p < 0.00001) 
from infancy to centenarians, while an age-dependent 
significant linear relationship (R2 = 0.216, p < 0.00001) 
was observed only from young to centenarians (Figure 
1B). No significant linear relationship was observed 
when all subjects were considered. When the mean 
galactosyltransferase activity of the six age groups was 
compared, significant differences were observed among 
the different classes (Figure 1C). By contrast, we observed 
significant differences between the ST6GAL1 activity of 
intermediate age groups and those of children and those 
above the age of 80 (Figure 1D). 
To investigate whether the increased activity of 
plasmatic B4GALTs and ST6GAL1 was due to a particular 
genetic background associated with extreme longevity, we 
measured the two activities in 19 offspring of centenarians 
(OC) and 19 sex and age-matched non long-lived parent 
offspring (NLPO). Details on both cohorts are reported in 
Materials and Methods. While the activity of B4GALTs 
was the same in the two groups (Figure 1E), ST6GAL1 
displayed a statistically significant (p < 0.05) 20% higher 
activity in OC, compared with NLPO (Figure 1F). 
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correlation between plasmatic glycosyltransferase 
activities and the GlycoAge test
Analysis by DSA-FACE of the N-glycans released 
from plasmatic glycoproteins provides a limited number 
of peaks, corresponding to N-linked chains of defined 
structures (Figure 2A and 2B). In particular, the Log of 
the ratio between peak 1 and peak 6, corresponding to 
core-fucosylated diantennary N-linked chains with two 
terminal galactose residues (peak 6 NA2F) or terminating 
with GlcNAc (peak 1 NGA2F) is the GlycoAge test. In 
Figure 2C is shown that the relationship between age 
and the GlycoAge test was linear in the range 24 years to 
centenarians. However, we show here for the first time that 
if children were included in the analysis, the GlycoAge 
test displayed a quadratic relationship with age, instead 
of the usual linear relationship. The GlycoAge test and 
the activities of plasmatic B4GALTs and ST6GAL1 all 
displayed a clear dependence on calendar age, although 
Figure 1: Plasmatic b4GALts and st6GAL1 activities in dependence of age. A., c., E. plasmatic B4GALTs; b., D., F. 
plasmatic ST6GAL1. A and B: regression analysis of enzyme activities in subjects of different ages; C and D: activity of the two enzymes in 
different age groups; E and F: activity of the two enzymes in offspring of centenarians (OC) or in age- matched offspring of non-long lived 
parents (NLPO). A: R2 linear (N = 125, all subjects) = 0.466; p < 0.00001. B: R2 quadratic (N = 125, all subjects) = 0.292; p < 0.00001; R2 
linear (N = 125, all subjects, dashed line) = 0.0001 p N.S.; R2 linear (N = 102, only adults) = 0.216; p < 0.00001. Comparison of the two 
glycosyltransferase activities in different age-groups (C and D) and in NLPO and OC (E and F). C-F: *p < 0.05; **p < 0.01; ***p < 0.001 
according to Kruskal-Wallis non parametric test.
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according to different patterns. To establish whether the 
three markers of aging were regulated in parallel, we 
performed correlation analysis of the three parameters 
after age-adjustments. A highly significant relationship 
existed between plasmatic B4GALTs activity and the 
GlycoAge test (p < 0.00001, Figure 2D). However, after 
age adjustment the significant relationship was lost (Figure 
2E, unstandardized residuals). This means that individuals 
of the same age group showing high GlycoAge test do 
not necessarily display a tendency toward high B4GALTs 
activity and vice versa. The relationship between 
GlycoAge test and ST6GAL1 activity was also significant 
(p = 0.0032, Figure 2F) and displayed little changes after 
age adjustment (Figure 2G). Also the relationship between 
ST6GAL1 and B4GALTs was not significant (Figure 
2H). These data suggested that the physio-pathological 
mechanisms at the basis of the GlycoAge test are probably 
similar to those at the basis of plasmatic ST6GAL1 but 
different from those at the basis of plasmatic B4GALTs. 
relationship of plasmatic glycosyltransferases 
with inflammatory and liver damage markers
The association of the two plasmatic 
glycosyltransferase activities with blood markers 
of inflammation/coagulation and liver damage was 
investigated in centenarians, OC and NLPO (Table 1). 
In centenarians only, it was observed a significant but 
negative association between GPT transaminase and 
B4GALTs activity. The lack of positive relationship 
between markers of liver damage and either plasmatic 
Figure 2: GlycoAge test and plasmatic glycosyltransferases. A. example of DSA-FACE analysis of glycans released by a plasma 
sample. The Log of the ratio of the relative abundance of peaks 1 and 6, whose structure is reported above, is the GlycoAge test. Peak 1 is 
the agalactosylated glycan also referred to as NGA2F present in IgG-G0. Peak 6 is its bigalactosylated counterpart also referred to as NA2F. 
b. Role of B4GALTs and of ST6GAL1 in the biosynthesis of N-glycans. Core-linked fucose is in parenthesis to indicate that its presence is 
not necessary for the activity of the two glycosyltransferases. c. correlation between the GlycoAge test and age in individuals from infancy 
to centenarians. Both the linear and quadratic relationships were significant (linear: R2 = 0.608; p <= 0.00001; quadratic: R2 = 0.689, p < 
0.00001), but the latter fit better. D. the highly significant relationship between the GlycoAge test and B4GALTs activity (R2 = 0.263; p = 
0.00001), was lost after age-adjustment E.. F. the significant relationship between the GlycoAge test and plasmatic ST6GAL1 activity (R2 = 
0.085; p = 0.0032) was maintained after age adjustment (R2 = 0.083; p = 0.0036) G. H. no significant relationship existed between plasmatic 
ST6GAL1 and B4GALTs activities (R2 = 0.003; p 0.561).
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glycosyltransferase activity suggested that the release 
of the two enzymes was not a consequence of liver cell 
injuries. Only in NLPO, we observed a close positive 
association between plasmatic ST6GAL1 and two acute 
phase proteins (C reactive protein and serum amyloid A) 
and TGF-1β, but not with inflammatory cytokines, such as 
IL-6 and TNF-α-resistin etc. 
Glycosylation of IgG heavy chains
The majority of plasmatic glycoproteins is 
synthesized by the liver; antibodies represent a remarkable 
exception, being synthesized by B lymphocytes and 
plasma cells. Owing to the very high level of ST6GAL1 
in hepatocytes, is not surprising that α2,6-sialylation 
is a major modification of plasmatic glycoproteins. To 
compare the level of α2,6-sialylation of antibodies with 
that of other plasmatic glycoproteins, diluted preparations 
of human plasma were analyzed by lectin blot, using the 
sialyl α2,6Gal/GalNAc-specific lectin from Sambucus 
nigra (SNA) as a probe [32]. Using undiluted plasma, 
a very large number of glycoproteins provided a very 
strong SNA signal, revealing that α2,6-sialylation is a very 
frequent modification (data not shown). For this reason 
we used 100 fold diluted plasma samples to identify and 
characterize only major α2,6-sialylated glycoproteins 
which were successively isolated as described in 
Figure 3: Age-dependent α2,6-sialylation of major plasmatic glycoproteins. A. One hundred fold diluted human plasma was 
analyzed by SNA lectin blot. The identity of the major SNA reactive bands, identified by MALDI-TOF/TOF mass spectrometry is indicated 
on the left. b. Quantification of SNA-reactive bands in the indicated four age groups. The mean ± SD of the SNA reactivity of the five 
identified glycoproteins in the four age groups is reported. Only the SNA-reactivity of IgG heavy chains showed a statistically significant 
age-dependent decrease (Student’s t test for independent samples).
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Table 1: Correlation between plasmatic B4GALT or ST6GAL1 activities and plasma markers in centenarians (CENT), 
offspring of centenarians (OC) and non-long lived parents offspring (NLPO).
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Figure 4: Lectin blot analysis of IgG glycosylation. Diluted plasma samples were analyzed after blotting with five lectins. In 
each gel, the reactivity associated with IgG heavy chains of plasma samples was normalized with that of fixed amounts of commercially 
available IgG, used as an internal standard. Correlation analysis indicated significant inverse linear relationship with age for SNA, ECL and 
E-PHA and a positive quadratic relationship for GSA-II. The structures recognized by each lectin is boxed. Structures in parenthesis can be 
present or absent without affecting recognition by the lectin.
Oncotarget7462www.impactjournals.com/oncotarget
Materials and Methods and identified by MALDI-TOF/
TOF analysis as thrombospondin-1, IgM heavy chain, 
fibrinogen β- and γ-chains and IgG heavy chain (Figure 
3A). Preliminary analysis of the level of α2,6-sialylation 
of the above mentioned glycoproteins in a limited group 
of children, young, old and centenarians was performed to 
establish which glycoprotein(s) displayed age-associated 
changes of α2,6-sialylation. As shown in Figure 3B, 
only the heavy chains of IgG underwent a dramatic and 
significant age-dependent decrease of α2,6-sialylation. 
Little or no age-dependent sialylation changes were 
displayed by glycoproteins of non-lymphocytic origin 
(thrombospondin-1 and fibrinogen β and γ chains) but 
also by IgM heavy chains. This indicates that the age-
dependent decrease of α2,6-sialylation observed in IgG 
heavy chains was very specific. Thus, further analysis 
was focused on IgG heavy chain glycosylation, using 
lectins specific for carbohydrate determinants known to be 
present on the Asn
297 
residue. The lectins from Erythrina 
cristagalli (ECL) specific for terminal galactose [33]; 
Griffonia simplicifolia II (GSA-II), specific for terminal 
GlcNAc [34]; erythroagglutinin from Phaseolus vulgaris, 
specific for bisecting GlcNAc [35] and Ulex europeus 
(UEA), specific for L-fucose [36] were used. An example 
of the lectin reactivity displayed by plasma samples and 
commercial IgG is shown in Supplementary Figure 1. The 
age-dependent variations of lectin reactivity are displayed 
in Figure 4. SNA reactivity showed a significant (p = 0.018 
after Bonferroni correction) age-dependent inverse linear 
relationship. In fact the reactivity progressively declined 
from infancy to centenarians. ECL reactivity displayed 
a similar trend with a significant (p = 0.0004 after 
Bonferroni correction) age-dependent reduction. GSA-II 
displayed a significant quadratic relationship (p = 0.0015) 
with high reactivity in children, decreased reactivity in 
young adults and a marked age-dependent progressive 
increase. E-PHA reactivity displayed a significant (p = 
0.004) linear decrease from children to centenarians, while 
no significant relationship with age was shown by UEA 
reactivity (Figure 4). 
The reactivity with GSA-II and ECL can be 
considered surrogates of peak 1 and 6 determined by 
DSA-FACE, respectively. In Figure S2A, is shown that 
the Log of the ratio between the reactivity with these two 
lectins [Log (GSA-II/ECL)] has a very good predictive 
value of calendar age (p < 0.0001). Correlation between 
the GlycoAge test and the Log(GSA-II/ECL) (Figure 2SB) 
was also highly significant (p < 0.0001).
To ascertain whether the age-associated changes 
of lectin reactivity were coordinately regulated, we 
performed correlation analysis between the reactivity of 
the different lectins (Figure 5). We observed that anti-
inflammatory glycotypes, such as α2,6-sialylation (SNA), 
terminal galactosylation (ECL) and terminal fucosylation 
(UEA), correlated each other and with bisecting GlcNAc 
(E-PHA). On the other hand, the pro-inflammatory 
terminal GlcNAc modification (GSA-II) did not 
correlate with SNA, UEA and E-PHA reactivity although 
unexpectedly it correlated with terminal galactosylation 
(ECL). These data indicate that anti-inflammatory sugar 
modifications of IgGs are often coordinately regulated. 
DIscUssION
The present work aims at shedding light in the 
complex balance of circulating pro-and anti-inflammatory 
molecules which are at the basis of the age-associated 
inflammatory status known as inflammaging [37]. Among 
Figure 5: correlation among lectin reactivities. A. The reactivity of each lectin was correlated with that of every other lectin 
evaluated. The significance of each pair is reported in b. Statistical significant relationships are indicated in bold.
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these molecules, antibodies play a relevant role and 
provide one of the best examples of how the biological 
functions of a glycoprotein are regulated by its sugar 
chains. The glycan linked to Asn
297
 of heavy chains can 
provide the IgG with pro- or anti-inflammatory roles by 
modulating the interaction of IgG with different effectors 
of the innate or adaptive immune system [38, 39]. In 
particular, IgG-G0 exert pro-inflammatory effects [40-
44], while core-fucosylated IgG exert anti-inflammatory 
effects by reducing ADCC [45, 46]. α2,6-sialylated IgG 
have been reported to be the main responsible of the 
powerful transient anti-inflammatory effect induced by 
the infusion of high doses human IgG (IVIG) [47, 48]. 
However, on the importance of α2,6-sialylation of IgG 
in IVIG conflicting results have been published [49-55]. 
Neither the origin of IgG-G0, nor that of α2,6-sialylated 
IgG [56, 57] has been unambiguously explained by the 
level of expression of the cognate glycosyltransferases 
in B-lymphocytes. Thus, the possibility of a pivotal role 
played by extracellular glycosylation, as demonstrated in 
mice for plasmatic ST6GAL1 [31, 58, 59] is intriguing.
Our results show for the first time that plasmatic 
B4GALTs activity exhibits a linear increase from infancy 
to extremely old age, while plasmatic ST6GAL1 activity 
is present at similar levels during adulthood, but is 
expressed at a high level only in infancy, old subjects and 
centenarians. However, neither enzyme showed a positive 
correlation with their cognate sugar structures on IgG 
(B4GALTs/galactosylation; ST6GAL1/α2,6-sialylation), 
strongly suggesting that extracellular glycosylation 
does not play a major role in determining the human 
antibody glycotype. The lost after age adjustment of the 
positive association between plasmatic B4GALTs and the 
GlycoAge test strongly suggests that the two parameters 
reflect different physio-pathological mechanisms. On 
the contrary, the positive relationship between plasmatic 
ST6GAL1 and the GlycoAge test, which was conserved 
after age-adjustment, suggests that the two parameters 
share a common physio-pathological mechanisms.
In rodents, ST6GAL1 behaves as an acute phase 
protein [60, 61] and plays a role in down-regulating 
inflammation. In fact, mice knock out for the hepatic 
ST6GAL1 promoter display a low levels of plasmatic 
ST6GAL1 and an exaggerated neutrophil accumulation 
in response to inflammatory stimuli [59]. It has been 
shown in mice that the extracellular sialylation of 
hematopoietic stem cells by plasmatic ST6GAL1 limits 
neutrophil production [58, 62, 63]. Altogether, these data 
are consistent with a model in which the inflammation-
dependent elevation of plasmatic ST6GAL1 has the 
effect of limiting the extent of the inflammatory response. 
Translating the data from experimentally inflamed mice 
to old humans, it can be hypothesized that the elevation 
of plasmatic ST6GAL1 is not a bad consequence of 
inflammaging but rather an attempt of the body to limit its 
adverse effects. This view is supported by the observation 
that the offspring of centenarians, who are at lower risk 
of inflammatory age-related diseases, have plasmatic 
ST6GAL1 activity higher than NLPO. Moreover, only in 
NLPO ST6GAL1 activity showed a positive association 
with some inflammatory markers, suggesting that the 
genetic background of OC can help ST6GAL1 to keep 
low the level of inflammation. The lack of a positive 
relationship between markers of liver damage and 
plasmatic B4GALTs or ST6GAL1 activities suggests that 
their level was not due to liver damage. Rather, it could 
be the result of an active proteolytic process which, for 
ST6GAL1, has been shown to be mediated by enzymes 
such as BACE1 [64-66]. 
The lectin blot approach we used, albeit limited 
by a lower throughput compared with DSA-FACE or 
mass spectrometry, offers the advantage of detecting 
glycosylation changes associated with specific 
glycoproteins and provides a clear cut answer to the 
presence/absence of a specific carbohydrate structure on 
IgGs heavy chains. Through this approach we documented 
changes of IgG glycosylation consistent with previous 
literature [12-16, 67-71]. The significant associations 
we observed between the reactivity with UEA, SNA and 
ECL, three lectins detecting sugar chains associated with 
an anti-inflammatory phenotype of IgGs, suggests the 
possibility of a coordinate regulation of glycosylation 
driving the inflammatory properties of IgG.
In conclusion, in this study we have identified a 
new marker of calendar age, plasmatic B4GALTs and 
revealed a more complex pattern of age-dependence of 
plasmatic ST6GAL1, suggestive of a possible role in 
limiting the effects of inflammaging. We have also shown 
that in humans, the glycosylation of antibodies is poorly 
affected by plasmatic glycosyltransferases, while in aging 
it undergoes a shift toward an inflammatory glycotype. 
MAtErIALs AND MEtHODs
Plasma samples
We studied 125 subjects of six different age groups: 
5-12 years (N = 23, mean age ±SD 7.6±1.95; M/F = 
17/6), 24-39 (N = 20, mean age 32.1±4.3; M/F = 10/10), 
40-60 (N = 13, mean age 53.3±5.3; M/F = 6/7), 61-80 
(N = 29, mean age 71.63±4.2; M/F = 14/15), 81-99 (N 
= 20, mean age 88.9±5.0; M/F = 11/ 9), 100-105 (N = 
20, mean age 100.4±2.0; M/F = 10/10). Additionally, a 
cohort of 19 offspring of centenarians (OC) (mean age 
72.9 ± 2.5; M/F = 10/9) was recruited and compared 
with 19 sex- and age-matched non-long lived parents 
offspring (NLPO). These individuals, (mean age 72.3 
± 2.5; M/F = 9/10) are included in the 61-80” group. 
NLPO have both parents born in the same birth cohort 
of centenarians (that is 1900-1908) but dead before the 
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threshold age over which subjects were classified as long-
lived as previously described [72]. Overnight fasting 
plasma samples were obtained in the morning and within 
2 hours from venipuncture by centrifugation at 2000 x g 
for 20 min at 4°C, rapidly frozen and stored at −80 °C. 
Subjects enrolled for evaluation of inflammatory status 
no used medication that could influence the inflammatory 
markers, such as steroid or nonsteroidal drugs and 
immunomodulatory agents, during the week before 
the blood drawn. Investigation has been conducted in 
accordance with the ethical standards and according to 
the Declaration of Helsinki and according to national and 
international guidelines and has been approved by the 
Ethical Committee of Sant’Orsola-Malpighi University 
Hospital (Bologna, Italy). Written consent was obtained 
from all subjects. For children, written consent was 
obtained from parents and also from children through 
pictures and simplified information. 
Plasmatic glycosyltransferase activities
β-galactoside α2,6-sialyltransferase (ST6GAL1) 
activity was measured in plasma specimens, devoid of any 
type of blood cell, using asialotransferrin as an acceptor, 
essentially as previously described [73, 74]. The reaction 
mixture contained in a final volume of 50 µl : 0.08 M Na-
cacodylate buffer pH 6.5, 5 µM unlabeled CMP-sialic 
acid and 1µl (0,001 mCi/ml) of CMP-[3H] sialic acid, 500 
µg asialotransferrin as acceptor glycoprotein and 5 µl of 
human plasma. After 3 hours at 37°C the acid-insoluble 
radioactivity was determined as previously described [73, 
74]. 
The reaction mixture for the determination of 
B4GALTs activity contained in a final volume of 20.5 µl, 
0.1 M Tris/HCl pH 8, 9.75 mM MnCl
2
, 4.9 mM CDP-
choline, 1 µl of UDP-[14C]Galactose (0.025 mCi/ml), 0.4 
mM ATP, 5 µl of plasma and 550 µg ovalbumin. After 3 
hs at 37 °C, the acid insoluble radioactivity was measured 
as described above. 
Lectin blot analysis
Ten microliters of plasma diluted 100 fold with 
waterBS were electrophoresed in reducing conditions 
according to Laemmli protocol [75]. The following 
lectins (Sigma) were labelled with digoxigenin (Roche) 
as indicated by the provider and used for the detection of 
the indicated sugar chains: Sambucus nigra (SNA) for 
α2,6-linked sialic acid [32]; Erythrina cristagalli (ECL) 
for terminal galactose [33]; Griffonia simplicifolia II 
(GSA-II), for terminal N-acetylglucosamine (GlcNAc) 
[34]; erythroagglutinin from Phaseolus vulgaris, for 
bisecting GlcNAc [35] and Ulex europeus, for L-fucose 
[36]. Blotting and detection were performed as previously 
described [76].
sNA-agarose precipitation
Four hundred microliters of plasma were brought to 
a final volume of 0.5 ml in PBS, containing 1% NP40, 1% 
deoxycholic acid, and protease inhibitors. Then, 20 µl of 
2 mg/ml SNA-biotin (Vector Laboratories, Burlingame, 
CA, USA) were added and the samples were stirred for 5 
h at 4 °C. Fifty microliters of streptavidin-agarose (Vector 
Laboratories) were then added and the samples were 
stirred overnight at 4 °C. Samples were then centrifuged 
in a minifuge and washed three times with PBS containing 
1% NP40, 1% deoxycholic acid, and protease inhibitors 
and once with 50 mM Tris-HCl, 15 mM NaCl. After 
centrifugation, samples were resuspended with reducing 
sample buffer, incubated at 60 °C 15 minutes and 
electrophoresed. 
GlycoAge test
N-glycans analysis was performed by DNA 
Sequencer-Aided, Fluorophore-Assisted Carbohydrate 
Electrophoresis (DSA-FACE) as described elsewhere 
[17]. Briefly, 5 µl of plasma were incubated with 2 µl of 
a denaturing buffer (5% SDS in 10 mM NH
4
HCO3) in a 
96 well plate, sealed and incubated for 5 min at 95°C. 
Enzymatic N-glycan release from the protein fraction was 
performed by adding 3 µL of a release mixture containing 
3.33% NP-40 and 33 Units of recombinant PNGase F 
(New England Biolabs) in 10 mM NH4HCO3, pH 8.3 and 
incubating for 3 h at 37°C. The released plasma N-glycans 
were then desialylated with 2 mU of Neuraminidase of 
Arthrobacter ureafaciens (Roche) in 5mM of NH4Ac, 
pH 5. 2 µl of the desialylated N-glycans were dried 
completely into a new plate, at 60°C for 1 h; after that, 
2 µL of fluorophore 8-amino-1,3,6-pyrenetrisulfonic acid 
(APTS) labeling buffer (1:1 mixture of 20 mM APTS in 
1.2 M citric acid and 1 M NaCNBH3 in DMSO) were 
added per sample. The reaction was stopped by adding 
150 µL of mQ water to each well. 10 μL of APTS labeled 
and desialylated glycans were analyzed using a CE-
based ABIA sequencer (Applied Biosystems).The data 
are processed by using Peak Scanner software (Applied 
Biosystem). We measured the intensities (heights) of 10 
N-glycans peaks and then normalized to the sum of the 
heights of all peaks. The GlycoAgeTest is evaluated by 
calculating the log of the ratio of the concentration of 
two diantennary N-glycans, both core fucosylated: an 
agalactosylated (NGA2F, or peak 1) and a digalactosylated 
(NA2F, or peak 6) [15]. 
statistical analysis
The relationship between age and plasmatic 
glycosyltransferenses and the GlycoAge test was assessed 
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by a linear regression analysis using age as independent 
variable, and each single variable as dependent variable. 
We performed the Kruskal-Wallis not parametric test 
to compare the different age-ranges and we reported 
the p-values calculated after Bonferroni correction for 
multiple comparisons.
In order to test the relationship between the 
GlycoAge test and either plasmatic glycosyltransferase, 
independently of the age effect, we regressed each 
parameter (GlycoAge test, plasmatic B4GALTs and 
ST6GAL1) on age of subjects. Subsequently, the 
unstandardized residuals of each of these age-adjusted 
parameters (GlycoAge test, plasmatic B4GALTs and 
ST6GAL1) were used for further linear regression 
analysis among these parameters (between GlycoAge 
test and plasmatic B4GALTs, between GlycoAge test and 
plasmatic ST6GAL1, as well as between ST6GAL1 and 
B4GALTs).
Correlation among plasmatic glycosyltransferases 
and inflammatory and liver damage markers were 
analyzed in centenarians, their offspring and non-long 
lived parents offspring and were presented as Spearman 
correlation coefficients. A two-tailed p-value of < 0.05 was 
considered significant. All analyses were carried out using 
SPSS for Machintosh, version 20.
MALDI/TOF-TOF identification of SNA-reactive 
glycoproteins
The selected protein bands were excised from the 
gel and processed for MALDI MS analysis following 
an already published procedure [77]. Briefly, the protein 
gel bands were washed, destained, reduced with DTT, 
alkylated with IAA, “in gel” digested with trypsin 
(Promega, Madison WI, USA) and the resulting peptides 
were extracted from the gel. Protein digests were desalted, 
concentrated and spotted onto a MALDI plate using 
ZipTips (Millipore, Billerica, MA, USA) following the 
manufacturer’s instructions. For the matrix preparation, a 
solution of 7-8 mg/ml α-cyano-4-hydroxycinnamic acid 
in 50% ACN/0.1% TFA was used. Samples were analyzed 
using a 4700 Proteomics Analyzer MALDI-TOF/TOF (AB 
SCIEX, Framingham, MA, USA). Peptide mass fingerprint 
(PMF) data were collected in positive MS reflector mode 
for the mass window m/z 700-4000 using trypsin autolysis 
peaks for internal calibration. Some of the highest 
intensity non-tryptic peaks were selected for MS/MS 
analysis. The MS and MS/MS spectra were analyzed using 
the software GPS Explorer (Version 3.6, AB SCIEX), and 
were searched together against the UniProtKB protein 
sequence database for the Homo sapiens taxonomic 
selection using the Mascot protein search engine (Version 
2.1.04, Matrix Science, UK). The search included peaks 
with a signal-to-noise ratio greater than 10, allowed for up 
to two missed trypsin cleavage sites. A fixed modification 
of cysteine (carbamidomethylation) and a variable 
modification of methionine (oxidation) were used in the 
search parameters. To be considered a match a confidence 
interval (CI), calculated by the AB SCIEX GPS Explorer 
software, of at least 99% was required. 
Determination of inflammatory and liver damage 
markers
Serum levels of glutamic-oxaloacetic transaminase 
(GOT), glutamic-pyruvic transaminase (GPT), gamma 
glutamyl transferase (GGT), C reactive protein (CRP), 
von Willebrandt Factor (vWF) were measured by 
standard biochemical methods in the clinical laboratory 
of S. Orsola Hospital, Bologna, Italy. Plasmatic levels of 
resistin, interleukine-6 (IL-6), interleukine-10 (IL-10), 
tumor necrosis factor-α (TNF-α) and amyloid A (SAA) 
were measured by multiplex sandwich ELISA technology 
(SearchLight, Aushon Biosystems, Billerica, MA) 
according to the manufacturer’s instructions and described 
previously [78]. 
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